Abilify Maintena (aripiprazole extended release)

Abilify Maintena (aripiprazole extended release)

Brand name: Abilify Maintena®

Active ingredient: Aripiprazole

Type: Atypical antipsychotic

Available from: Otsuka Canada + Lundbeck Canada

Form: Long‑acting injectable

Generic: No

Listed on Ontario formulary: Yes (with suggested criteria*).

OHIP+ coverage: Yes (with suggested criteria*).

*Suggested for individuals with non‑adherence AND either

1. inadequate control or significant side effects on 2+ oral antipsychotics (including an atypical), OR
2. inadequate control or side effects on a typical depot antipsychotic.

Note: The tablet form is sold as Abilify®.

What is Abilify Maintena used for?

Maintenance treatment of schizophrenia and other psychotic disorders in adults.
May be used for bipolar disorder depending on prescriber judgment.

How should I take Abilify Maintena?

A long‑acting intramuscular injection administered by a healthcare professional.
Usually given once every 4 weeks.

Available as 300 mg and 400 mg vials.

The typical dose is 400 mg every 4 weeks, with a 14‑day overlap of oral antipsychotic at initiation.

Common side effects

Same as oral Abilify, plus:

• Injection‑site pain

Rare but serious side effects

Same as oral Abilify.

Warnings/Precautions

Same impulse‑control and dementia‑related psychosis warnings as oral Abilify.

Medication interactions

Same as oral Abilify.